Richard Chin, MD
Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.
Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.
Stephen Sundlof, DVM, PhD
Steve Sundlof served as the Director of the Center for Veterinary Medicine at the FDA from 1994 to 2008 where he oversaw all veterinary products regulated by the FDA. He also served as the Director of Center for Food Safety and Applied Nutrition at the FDA from 2008 to 2010. Steve began his career in 1980 on the faculty of the University of Florida’s College of Veterinary Medicine. In 1994, FDA Commissioner David Kessler named him the CVM director.